AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Abstract Background Among patients with non-metastatic pancreatic cancer, 80% have high-risk, borderline resectable or locally advanced cancer, with a 5-year overall survival of 12%. MASTERPLAN evaluates the safety and activity of stereotactic body radiotherapy (SBRT) in addition to chemotherapy in...

Full description

Bibliographic Details
Main Authors: Andrew Oar, Mark Lee, Hien Le, Kate Wilson, Chris Aiken, Lorraine Chantrill, John Simes, Nam Nguyen, Andrew Barbour, Jaswinder Samra, Katrin M. Sjoquist, Alisha Moore, David Espinoza, Val Gebski, Sonia Yip, Julie Chu, Andrew Kneebone, David Goldstein
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Pancreas
Stereotactic radiotherapy
SBRT
Modified FOLFIRINOX
mFOLFIRINOX
Online Access:https://doi.org/10.1186/s12885-021-08666-y

Internet

https://doi.org/10.1186/s12885-021-08666-y

Similar Items